ARS Pharmaceuticals Elevates Donn Casale to CEO After Founder Lowenthal's Decade-Long Tenure
SPRY•Co-founder and CEO Richard Lowenthal will leave ARS Pharmaceuticals on July 6, 2026, after more than a decade leading the company. The board appointed President Donn Casale, who scaled HEPLISAV-B to over $300 million in annual revenue, as CEO and director effective July 7, 2026.
1. CEO Succession Details
The board of ARS Pharmaceuticals announced that co-founder and CEO Richard Lowenthal will step down as an employee and officer effective July 6, 2026. President Donn Casale has been appointed CEO and director effective July 7, 2026 to guide the company’s next phase.
2. Casale's Commercial Track Record
Donn Casale brings more than 25 years of biopharmaceutical leadership, including building Dynavax’s HEPLISAV-B vaccine to over $300 million in annual revenue and more than 50% U.S. market share. He also supported the commercialization of GRALISE®, NUCYNTA® and led strategic roles at Merck.
3. Strategic Outlook for neffy
Under Casale’s leadership, ARS Pharmaceuticals aims to accelerate adoption and market penetration of neffy intranasal epinephrine, expand patient access, and drive long-term value creation by leveraging his proven commercial and operational expertise.
